Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
Li X, Cheng K, Li X, Zhou Y, Liu J, Zeng H, Chen Y, Liu X, Zhang Y, Wang Y, Bi F, Zheng L.
Li X, et al. Among authors: zheng l.
Int J Cancer. 2021 Oct 1;149(7):1473-1482. doi: 10.1002/ijc.33706. Epub 2021 Jul 7.
Int J Cancer. 2021.
PMID: 34109624
Clinical Trial.